详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

54| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]West China Hospital of Sichuan University, Sichuan University, Chengdu, China. [2]Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [3]College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China. [4]State Key Laboratory for Oncogenes and Related Genes, Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai, China. [5]The College of Life Science, Sichuan University, Chengdu, China. [6]Department of Laboratory Medicine, Liuzhou People's Hospital, Liuzhou, China. [7]Guangxi Health Commission Key Laboratory of Clinical Biotechnology (Liuzhou People's Hospital), Liuzhou, China. [8]Guangxi Medical University Cancer Hospital, Nanning, China. [9]Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, China. [10]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [11]Zhongshan Hospital of Fudan University, Xiamen, Fujian, China. [12]Department of Organ Transplantation, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China. [13]Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.

出处：

DOI：

关键词： non-small cell lung cancer targeted therapy immunotherapy mechanisms of drug resistance promising strategies

摘要：

Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge in the treatment of this disease. The mechanisms of resistance are multifactorial and include molecular target alterations and activation of alternative pathways, tumor heterogeneity and tumor microenvironment change, immune evasion, and immunosuppression. Promising strategies for overcoming resistance include the development of combination therapies, understanding the resistance mechanisms to better use novel drug targets, the identification of biomarkers, the modulation of the tumor microenvironment and so on. Ongoing research into the mechanisms of resistance and the development of new therapeutic approaches hold great promise for improving outcomes for patients with NSCLC. Here, we summarize diverse mechanisms driving resistance to targeted therapy and immunotherapy in NSCLC and the latest potential and promising strategies to overcome the resistance to help patients who suffer from NSCLC.Copyright © 2024 Xiang, Liu, Wang, Zheng, Meng, Jiang, Yang, Zhang, Zhang, Liu and Wang.

基金：

语种：

被引次数：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 5.7 出版当年[2023版] 0 出版当年五年平均 5.7 出版前一年[2023版]

第一作者：

第一作者机构： [1]West China Hospital of Sichuan University, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [2]Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [13]Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

文献详情

相关文献